** Shares of Neurizon Therapeutics fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024
** Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020
** Biotech firm receives notification from the U.S. FDA that its investigational new drug $(IND.AU)$ application for NUZ-001 to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, has been put under clinical hold
** IND application is a request for authorisation to administer experimental drugs to humans
** Co says FDA has outlined certain concerns over sufficiency of information to assess application
** More than 2.9 mln shares change hands, 7.1 times the 30-day avg
** Neurizon down 26.5% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。